• November 26, 2024

Amgen falls after obesity study results

 Shares of Amgen (NASDAQ: NASDAQ: AMGN ) dropped 12% Tuesday following the release of Phase 2 trial results for its obesity drug candidate, MariTide (formerly AMG 133). While the...

0.099969s